Advancing next-generation proteomics with single-molecule Iterative Mapping
Wednesday, January 14 at 17:00 GMT | 18:00 CET | 12:00 EST | 09:00 PST
Discover how Iterative Mapping is helping to reshape proteomic analysis. This single-molecule approach enables comprehensive proteome profiling with high sensitivity and quantitative accuracy, allowing researchers to study proteins and proteoforms across the full complexity of the proteome.
Rather than focusing solely on protein detection, Iterative Mapping captures information at the level of individual protein molecules, supporting robust quantification of defined proteins and proteoforms and generating datasets suitable for advanced computational and AI-driven analysis.
In this webinar, Dr. Birgit Schilling, Professor and Director of the Mass Spectrometry Core at the Buck Institute for Research on Aging, will share how her laboratory is applying Iterative Mapping to investigate tau proteoforms and their role in aging and age-associated neurodegenerative disease. She will discuss how molecule-level protein analysis is enabling new insights into proteoform heterogeneity and biological function that are difficult to achieve using conventional proteomic approaches.
Dr. Parag Mallick and Dr. Sheri Wilcox of Nautilus Biotechnology will then place these findings in a broader proteomics context, presenting data that illustrate the quantitative performance of Iterative Mapping in complex protein mixtures and disease-relevant proteoforms, including tau.
Dr. Mallick and Dr. Wilcox will also discuss how Nautilus Biotechnology can work with clients to bring Iterative Mapping into their lab.
Key learning objectives:
- Discover the quantitative benefits of Iterative Mapping for proteomics analysis
- Explore how Iterative Mapping opens new research pathways and may deeply enhance biological understanding
- Learn how you can work with Nautilus Biotechnology to bring Iterative Mapping into your lab
Who should attend?
- Genomics, transcriptomics, and other ‘omics or multiomics researchers looking for a new and accessible way to incorporate proteomics into their workflows.
- Proteomics researchers looking to interrogate the full proteome at scale more deeply.
- Neuroscientists interested in learning how tau and its many proteoforms shape their biology of interest.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Birgit Schilling, Ph.D., is Director of the Mass Spectrometry Core and Professor at the Buck Institute for Research on Aging, and Adjunct Professor at USC. Trained in Chemistry in Germany and postdoctoral work at UCSF, she joined the Buck Institute in 2000. Her research applies advanced mass spectrometry to study protein expression and modifications in aging, neurodegeneration, cancer, and other diseases. She develops new proteomics workflows and technologies and leads projects on sarcopenia and sirtuin-regulated posttranslational modifications. As President of US HUPO, Dr. Schilling advances proteomics globally. She also frequently collaborates with biotech partners including BioMarin, Sirtris, MitoSciences, and Unity Biotechnology.
Dr. Parag Mallick obtained his Ph.D. in Chemistry and Biochemistry from UCLA, where he worked with Dr. David Eisenberg. He then completed his post-doctoral training with proteomics pioneer Ruedi Aebersold at the Institute for Systems Biology, where he worked on defining the biophysical origins of proteotypic peptides. He also did early work in proteogenomics and proteomics-based biomarker discovery. As an Associate Professor at Stanford, his lab uses a mix of quantitative proteomics, machine learning, and nanotechnology to perform systems biology studies of cancer initiation and progression that drive precision medicine approaches for cancer diagnosis and treatment. He is the founder and chief scientist of Nautilus Biotechnology, a company developing a large-scale, single-molecule platform for comprehensively quantifying the proteome.
Dr. Sheri Wilcox spent 21 years at SomaLogic where she was instrumental in the development of the SomaScan Platform and SOMAmer reagents. As Associate Director of Aptamer Discovery she guided research of aptamers for biomarker discovery and directed the high-throughput generation of SOMAmer reagents/ As Senior Director of Analytical and Discovery Sciences, she led SOMAmer discovery and characterization efforts, as well as several collaborations. Before joining SomaLogic, she was a postdoctoral fellow at Pharmacia, prior to its merger with Pfizer Inc. Dr. Wilcox received her B.S. in chemistry from Vanderbilt University, and her Ph.D. in macromolecular and cellular structure and chemistry from Scripps Research.
Moderator
